Nanoparticulate Drug Delivery Perspectives on the Transition from Laboratory to Market 1st Edition by Vandana Patravale, Prajakta Dandekar, Ratnesh Jain ISBN 1907568980 9781907568985

Nanoparticulate Drug Delivery Perspectives on the Transition from Laboratory to Market 1st Edition by Vandana Patravale, Prajakta Dandekar, Ratnesh Jain – Ebook PDF Instant Download/Delivery: 1907568980, 9781907568985
Full download Nanoparticulate Drug Delivery Perspectives on the Transition from Laboratory to Market 1st Edition after payment

Product details:

ISBN 10: 1907568980 
ISBN 13: 9781907568985
Author: Vandana Patravale, Prajakta Dandekar, Ratnesh Jain

Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate systems as drug carriers, including the assessment of their morphology, sterility and potential toxicity. In the latter part of the book, chapters cover nanotoxicology, regulatory aspect and clinical trials, ending with an overview of several case studies and a look towards future developments.

• Discusses the issues surrounding nanoparticulate products, based on personal experience of their formulation
• Provides an overview of new application areas, including RNA interference
• Outlines the pros and cons of nanoparticulate products, and discusses how these may influence their route into the commercial sector

Nanoparticulate Drug Delivery Perspectives on the Transition from Laboratory to Market 1st Table of contents:

1 Nanoparticulate systems as drug carriers: the need
1.1 Introduction: nanoparticles for drug delivery
1.2 Need: solubility, bioavailability, targeting and more
1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations
1.4 References
2 Nanoparticles as drug carriers
2.1 Nanoparticles as drug carriers: the scope
2.2 Nanoparticles as drug delivery carriers
2.3 Application areas for nanoparticulate drug delivery systems
2.4 Routes of administration of nanoparticulate drug delivery systems
2.5 Conclusion
2.6 References
3 Characterization techniques for nanoparticulate carriers
3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers
3.2 Measuring the size of nanoparticles
3.3 Zeta potential measurement
3.4 Characterizing the morphology of the nanoparticles
3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles
3.6 Toxicity evaluation of nanoparticles
3.7 Evaluating immunological potential of nanoparticles
3.8 References
4 Nanotoxicology: evaluating toxicity potential of drug-nanoparticles
4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems
4.2 In vitro assays for assessing toxicity of nanoparticles
4.3 In-vivo assays for assessing toxicity of nanoparticles
4.4 Genotoxicity evaluation
4.5 References
5 Regulatory aspects of nanoparticulate drug delivery systems
5.1 Nanoparticulate drug carriers: the regulatory facet
5.2 Issues associated with regulating nano-drug delivery systems
5.3 Current approaches for regulating pharmaceutical nanocarriers
5.4 References
6 Clinical trials and industrial aspects
6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures
6.2 Case studies: cancer
6.3 Case studies: other diseases
6.4 Nanoparticulate drug delivery: an industrial outlook
6.5 References
7 Case studies: nano-systems in the market
7.1 Case studies: performance and market approval
7.2 Are nano or conventional drug delivery systems a better choice? – a market overview
7.3 Future perspectives on nanoparticulate drug carriers
7.4 References

People also search for Nanoparticulate Drug Delivery Perspectives on the Transition from Laboratory to Market 1st:

nanoparticulate drug delivery perspectives transition
    
nanoparticle drug delivery systems
    
nanoparticle drug delivery
    
nanoparticles delivery
    
nanoparticle delivery system

Tags:

Vandana Patravale,Prajakta Dandekar,Ratnesh Jain,Nanoparticulate Drug,Laboratory,Market